User login
Key clinical point: Both overall survival and progression-free survival rates were significantly higher in patients with unresectable HCC who were treated with TACE-MWA compared to those treated with TACE alone.
Major finding: After propensity score matching, the 1-, 2-, and 3-year overall survival rates for patients treated with TACE-MWA were 93.6%, 80.5%, and 61.6%, respectively, compared to 72.4%, 48.9%, and 41.9%, respectively, in patients treated with TACE alone group, respectively.
Study details: The data come from a propensity score matching study of 91 adults with unresectable HCC who underwent transarterial chemoembolization (TACE) plus percutaneous microwave ablation (MWA) and 140 who underwent TACE alone at four medical centers.
Disclosures: The study was supported by the National Natural Science Foundation of China. The researchers had no financial conflicts to disclose.
Source: Li H-Z et al. J Hepatocell Carcinoma. 2021 Nov 1. doi: 10.2147/JHC.S338456.
Key clinical point: Both overall survival and progression-free survival rates were significantly higher in patients with unresectable HCC who were treated with TACE-MWA compared to those treated with TACE alone.
Major finding: After propensity score matching, the 1-, 2-, and 3-year overall survival rates for patients treated with TACE-MWA were 93.6%, 80.5%, and 61.6%, respectively, compared to 72.4%, 48.9%, and 41.9%, respectively, in patients treated with TACE alone group, respectively.
Study details: The data come from a propensity score matching study of 91 adults with unresectable HCC who underwent transarterial chemoembolization (TACE) plus percutaneous microwave ablation (MWA) and 140 who underwent TACE alone at four medical centers.
Disclosures: The study was supported by the National Natural Science Foundation of China. The researchers had no financial conflicts to disclose.
Source: Li H-Z et al. J Hepatocell Carcinoma. 2021 Nov 1. doi: 10.2147/JHC.S338456.
Key clinical point: Both overall survival and progression-free survival rates were significantly higher in patients with unresectable HCC who were treated with TACE-MWA compared to those treated with TACE alone.
Major finding: After propensity score matching, the 1-, 2-, and 3-year overall survival rates for patients treated with TACE-MWA were 93.6%, 80.5%, and 61.6%, respectively, compared to 72.4%, 48.9%, and 41.9%, respectively, in patients treated with TACE alone group, respectively.
Study details: The data come from a propensity score matching study of 91 adults with unresectable HCC who underwent transarterial chemoembolization (TACE) plus percutaneous microwave ablation (MWA) and 140 who underwent TACE alone at four medical centers.
Disclosures: The study was supported by the National Natural Science Foundation of China. The researchers had no financial conflicts to disclose.
Source: Li H-Z et al. J Hepatocell Carcinoma. 2021 Nov 1. doi: 10.2147/JHC.S338456.